Last chance to register: Is NGS the new normal for pathogen detection?

Is this email not displaying correctly? [View it in your browser](. Dear {NAME}, You're invited to join our webinar entitled: Is NGS the new normal for pathogen detection? Date: Wednesday, October 21st Time: 2:00 PM EDT The unprecedented pathogenic spread of COVID-19 has created a global economic and public healthcare crisis, with communities and countries continuing to respond to the outbreaks. Several technologies have been adapted for rapid detection and surveillance of the underlying SARS-CoV-2 viral pathogen and NGS has emerged as a potential technological solution to meet the needs for large-scale testing. This webinar will provide unique perspectives across academia and industry on the use of NGS technologies to address SARS-CoV-2 pathogen detection. Three 15- to 20-minute technical presentations will be followed by a panel discussion on whether NGS technologies will serve as a new basis for detection of pathogen outbreaks. Keith Robison, Ginkgo Bioworks Development of a scalable, short read assay for high throughput COVID-19 screening The COVID-19 pandemic has spurred technological innovations for pathogen detection and surveillance. Concentric by Ginkgo™ is a scalable assay for detecting SARS-CoV-2 in saliva which uses short read sequencing to sensitively detect amplicons generated by RT-PCR. I will review some of the technical challenges the Ginkgo team has encountered and how we have used closely coupled computational and experimental methods to dissect and address these challenges. Katherine Siddle, Broad Institute The added value of genome sequencing in SARS-CoV-2 SARS-CoV-2, the etiological agent of COVID-19, has caused over 35 million cases globally, and almost 150,000 SARS-CoV-2 genomes from patients have been sequenced and shared. In addition to offering a sensitive alternative for testing for the presence of SARS-CoV-2, genome sequencing provides additional resolution enabling the investigation of the introduction, spread and biology of SARS-CoV-2. To investigate these features of SARS-CoV-2, the Sabeti lab at the Broad Institute assembled over 800 genomes from COVID-19 cases between January and June of 2020 to provide a detailed picture of the arrival and transmission of SARS-CoV-2 in the Boston area. To do so, we performed optimization of both metagenomic and amplicon sequencing approaches and established a semi-automated workflow allowing us to significantly increase scale and throughput. Phylogenetic analysis of 772 complete SARS-CoV-2 genomes identified over 80 introductions to the Boston area and highlighted the importance of superspreading events in SARS-CoV-2 transmission. These results provide examples of how sequencing capacity can be rapidly expanded and the value that these insights can bring to contact tracing and other public health measures. David O’Connor, University of Wisconsin WIn-now: SARS-CoV-2 LAMP testing and sequencing to mitigate risk in schools Rapid turnaround and frequent SARS-CoV-2 testing is essential to mitigate disease transmission and enable the return to in-person school. We developed a non-diagnostic, non-CLIA mobile lab to perform LAMP testing on saliva. More than 2,500 volunteers have been tested to date, with few false positives and few false negatives. True positives have been urged to isolate and obtain diagnostic testing as soon as possible. At the same time, we are coupling testing with sequencing viruses from the community to better understand the risk of returning to in-person K-12 schooling. Unable to attend the live webinar? All registrants will receive a link to view the recording on demand. [blank] [blank] [blank] New England Biolabs, Inc. Telephone: (978) 927-5054 Toll Free: (U.S. Orders) 1-800-632-5227 Toll Free: (U.S. Tech) 1-800-632-7799 info@neb.com [NEB Facebook]( [NEB Twitter]( [NEB YouTube]( [NEB LinkedIn]( --------------------------------------------------------------- Do you know someone who may be interested in attending? Share with a colleague: [Forward This]( UK) [blank] One or more of these products are covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc. For more information, please contact NEB's Global Business Development team at gbd@neb.com. The use of these products may require you to obtain additional third party intellectual property rights for certain applications. Your purchase, acceptance, and/or payment of and for NEB's products is pursuant to NEB's [terms of sale.]( NEB does not agree to and is not bound by any other terms or conditions, unless those terms and conditions have been expressly agreed to in writing by a duly authorized officer of NEB. © Copyright 2020, New England Biolabs, Inc.; All rights reserved. New England Biolabs is an ISO 9001, ISO 14001 and ISO 13485 certified facility. NEB does not intend to inundate you with email messages. If you would like to update your email preferences or unsubscribe from the list, please [click here.](